The botanical alkaloid BBR has also been identified as a novel drug for the treatment of multiple myeloma (MM) through targeting the molecular mechanism UHRF1 (ubiquitin-like with PHD and RING Finger domains 1). This evidence concerns the gene UHRF1 and plasma cell myeloma.